AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Capital Expenditures · Q4 FY2024 · quarter ended Dec 2024
Capital expenditures of -€363K in Q4 FY2024
Q4 FY2024 capital expenditures was -€363K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
Currency unavailable · from the cash flow
No Capital Expenditures data reported for this period type.
Capital Expenditures vs competitors
How AGMB compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $401K USD | -77.7% | -35.3% | 5.4% |
| LTM Mar 2026 | $81K USD | -99.8% | -43.2% | 1.0% | |
| LTM Mar 2026 | $69K USD | -81.1% | -37.6% | 0.0% | |
| LTM Mar 2026 | $47K USD | -32.9% | -44.4% | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -79.4% | -40.4% | 1.0% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.